Who is sponsoring NCT02762136?

NCT02762136 is sponsored by Xiyuan Hospital of China Academy of Chinese Medical Sciences.

What condition does NCT02762136 study?

NCT02762136 studies Postprandial Distress Syndrome.

What drugs are being tested in NCT02762136?

Interventions: placebo, Xiang-sha-liu-jun granules.

What is the status of NCT02762136?

NCT02762136 is currently UNKNOWN.

Last reviewed 2016-05-04 · How we verify

Xiang-sha-liu-jun Granules as an Herbal Formula for the Treatment of Postprandial Distress Syndrome(PDS): a Prospective, Double-blinded, Randomized and Placebo-controlled,Three-center Trial

NCT02762136 Phase 1/Phase 2 UNKNOWN

Functional dyspepsia (FD), which is one of the most common gastrointestinal disorders with high disease burden. Postprandial distress syndrome (PDS) is a common subtype of FD. Although the effectiveness of Chinese herbal formula of Xiang-sha-liu-jun granule (XSLJG) for alleviating PDS symptoms has been assessed in previous studies, more convinced evidence of randomized placebo-controlled study is needed.

Details

Lead sponsor	Xiyuan Hospital of China Academy of Chinese Medical Sciences
Phase	Phase 1/Phase 2
Status	UNKNOWN
Enrolment	216
Start date	2015-08
Completion	2018-04

Conditions

Postprandial Distress Syndrome

Interventions

placebo
Xiang-sha-liu-jun granules

Primary outcomes

change of postprandial discomfort severity Scale — Postprandial Discomfort Severity Scale at baseline, 2 weeks, and 4 weeks during oral administration of medicine

Countries

China